360b / Shutterstock.com
Pharmaceutical companies including Cipla and Natco Pharma have signed a sub-licensing deal enabling them to produce a generic version of Bristol Myers Squibb’s (BMS) hepatitis C drug Daclatasvir (daklinza).
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Cipla, Natco, Emcure, Hetero, Bristol Myers Squibb, Hepatitis C, paye, daclatasvir, Greg Perry, Medicines Patent Pool, MPP, Rajeev Nannapaneni, Vik Thapar,
